Michael A. Postow, MD | Authors

Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?

May 15, 2018

In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy.

CTLA-4 Antibodies: New Directions, New Combinations

November 11, 2014

This review will summarize the preclinical and clinical development of CTLA-4–blocking antibodies, discuss recent insights into the biology of CTLA-4 blockade, review the use of these antibodies in combination with established and novel therapeutic modalities, and comment on ongoing questions regarding their administration.